Arteriovenous fistula patency in the 3 years following vonapanitase and placebo treatment

作者：Peden Eric K; O'Connor Timothy P; Browne Barry J; Dixon Bradley S; Schanzer Andres S; Jensik Stephen C; Sam Albert D II; Burke Steven K^*

来源：Journal of Vascular Surgery, 2017, 65(4): 1113-1120.

DOI：10.1016/j.jvs.2016.08.101

Objective: This study explored the long-term outcomes of arteriovenous fistulas treated with vonapanitase (recombinant human elastase) at the time of surgical creation.
Methods: This was a randomized, double-blind, placebo-controlled trial of 151 patients undergoing radiocephalic or brachiocephalic arteriovenous fistula creation who were randomized equally to placebo, vonapanitase 10 mg, or vonapanitase 30 mg. The results after 1 year of follow-up were previously reported. The current analysis occurred when the last patient treated was observed for 3 years. For the current analysis, the primary end point was primary patency; the secondary end points included secondary patency, use of the fistula for hemodialysis, and rate of procedures to restore or to maintain patency.
Results: There was no significant difference in the risk of primary patency loss with vonapanitase 10 mg or 30 mg vs placebo. When seven initial patency loss events related to cephalic arch and central vein balloon angioplasty were excluded, the risk of patency loss was reduced with vonapanitase overall (hazard ratio [HR], 0.63; P =.049) and 30 mg (HR, 0.51; P =.03). In patients with radiocephalic fistulas (n = 67), the risks of primary and secondary patency loss were reduced with 30 mg (HR, 0.37 [P =.02] and 0.24 [P =.046], respectively). The rate of procedures to restore or to maintain fistula patency was reduced with 30 mg vs placebo (0.23 vs 0.72 procedure days/patient/year; P =.03) and also reduced in patients with radiocephalic fistulas with 30 mg vs placebo (0.17 vs 0.85 procedure days/patient/year; P =.048).
Conclusions: In this study, vonapanitase did not significantly improve primary patency in the primary analysis but did significantly improve primary patency in an analysis that excluded patency loss due to cephalic arch and central vein balloon angioplasty. In patients with radiocephalic fistulas, 30 mg significantly improved primary and secondary patency. Vonapanitase 30 mg decreased the rate of procedures to restore or to maintain patency in the analysis that included all patients and in the subset with radiocephalic fistulas.

• 出版日期2017-4